MARKET

ALT

ALT

Altimmune
NASDAQ
3.610
0.000
0.00%
After Hours: 3.600 -0.01 -0.28% 19:23 12/31 EST
OPEN
3.600
PREV CLOSE
3.610
HIGH
3.625
LOW
3.520
VOLUME
4.29M
TURNOVER
--
52 WEEK HIGH
7.83
52 WEEK LOW
2.900
MARKET CAP
376.36M
P/E (TTM)
-3.3773
1D
5D
1M
3M
1Y
5Y
1D
BUZZ-Structure Therapeutics doubles while other obesity drug developers decline
Reuters · 12/31/2025 14:29
Altimmune Director Diane Jorkasky Acquires Common Shares
Reuters · 12/29/2025 21:10
3 Beaten-Down Biotech Stocks to Buy for a 2026 Turnaround
NASDAQ · 12/29/2025 15:15
Weekly Report: what happened at ALT last week (1222-1226)?
Weekly Report · 12/29/2025 09:04
Altimmune, Pure Storage, Globalstar, Cipher Mining, AutoZone Shake-Up
TipRanks · 12/27/2025 13:00
Friday 12/26 Insider Buying Report: AGIG, ALT
NASDAQ · 12/26/2025 19:10
Altimmune’s IMPACT NASH Trial Completion Puts Pemvidutide Back in the Spotlight
TipRanks · 12/26/2025 16:30
Insider Makes Bold Move on Altimmune Stock With Fresh Buy
TipRanks · 12/24/2025 02:03
More
About ALT
Altimmune, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing next-generation peptide-based therapeutics. It is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity, metabolic dysfunction-associated steatohepatitis (MASH) and other indications. Activation of the GLP-1 and glucagon receptors is believed to mimic the complementary effects of diet and exercise on weight loss, with GLP-1 suppressing appetite and glucagon increasing energy expenditure. Glucagon is also recognized as having direct effects on hepatic fat metabolism, to rapid reductions in levels of liver fat and serum lipids. The Company has completed the MOMENTUM Phase II obesity trial and is being studied in the IMPACT Phase IIb MASH trial. The Company also develops and commercializes surfactant-functionalized (EuPort domain) incretin-based peptide therapeutics, including (GLP-1-glucagon)/oxyntomodulin, and variants.

Webull offers Altimmune Inc stock information, including NASDAQ: ALT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ALT stock methods without spending real money on the virtual paper trading platform.